AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
Mycobacterium Abscessus Load Reduced by 65% NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage ...